Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

Introduction Methods and analysis Pathology-confirmed WHO type II/III NPC patients at clinical stage III–IVA (eighth American Joint Committee on Cancer/Union for International Cancer Control staging system) will be included in the study. They will receive ICT plus nimotuzumab (NTZ), followed by radi...

Full description

Bibliographic Details
Main Authors: Yan Liu, Jing-Jing Yuan, Jian-Wu Ding, Jin-Wei Li, Rong-Huan Hu, Dan Gong, Jia-Li Hu, Kai-Bin Zhu, Yu-Hai Ding, Jia-Wang Wei, Jian-Lun Zeng, Zhi-Bing Lu, Wei-Hua Yin, Su-Fen Ai, Guo-Hua Zha, Zhi-Lin Zhang, Rui Zou, Lei Zeng
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/8/e051594.full

Internet

https://bmjopen.bmj.com/content/12/8/e051594.full

Similar Items